Company: PTHS
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001753926-25-000790
Chunk: 49

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 49
---

    549,630

    679,815

    (130,185
    ) 

    (19
    )%

    Total
    operating expenses

    1,833,977

    1,933,982

    (100,005
    ) 

    (5
    )%

    Loss
    from operations

    (1,833,977
    )

    (1,933,982
    )

    100,005

    (5
    )%

    Other
    expense

    (133,634
    )

    (628,348
    )

    494,714

    (79
    )%

    Net
    loss before provision for income taxes

    (1,967,611
    )

    (2,562,330
    )

    594,719

    (23
    )%

    Provision
    for income taxes

    —

    —

    —

    NA

    Net
    loss
     
    $
    (1,967,611
    )

    (2,562,330
    )

    594,719

    (23
    )%

Operating
Expenses

Our
operating expenses consist of general and administrative expenses, research and development expenses and professional fees.

General
and Administrative Expenses

We
incurred general and administrative expenses for the three months ended March 31, 2025 and 2024 of $1,090,049 and $787,561, respectively.
For the three months ended March 31, 2025, compared to the same period in 2024, this represented an increase of $302,488, or 38%,
primarily as a result of increases of $173,686 in compensation expenses and an increase of $163,279 in stock compensation.

Research
and Development Expenses

We
incurred research and development expenses for the three months ended March 31, 2025 and 2024 of $194,298, and $466,606, respectively.
For the three months ended March 31, 2025, compared to the same period in 2024, this represented a decrease of $272,308, or 58%,
with the details set forth in the table below:

    Three
    Months Ended March 31, 2025 and 2024

    2025

    2024

    $
    Change

    %